HASHEM EL-SERAG to Drug Therapy, Combination
This is a "connection" page, showing publications HASHEM EL-SERAG has written about Drug Therapy, Combination.
Connection Strength
0.862
-
Lessons From Using Culture-Guided Treatment After Referral for Multiple Treatment Failures for Helicobacter pylori Infection. Clin Gastroenterol Hepatol. 2018 09; 16(9):1531-1532.
Score: 0.448
-
Current Status of Chemoprevention in Barrett's Esophagus. Gastrointest Endosc Clin N Am. 2021 Jan; 31(1):117-130.
Score: 0.136
-
Epidemiology, screening, diagnosis and treatment of hepatocellular carcinoma. Minerva Gastroenterol Dietol. 2009 Jun; 55(2):123-38.
Score: 0.062
-
Impact of an Electronic Medical Record Quality Improvement Intervention on Helicobacter pylori Treatment and Eradication Rates in a U.S. Hospital System. Helicobacter. 2025 Mar-Apr; 30(2):e70034.
Score: 0.046
-
Meta-analysis: proton pump inhibitor or H2-receptor antagonist for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2003 May 15; 17(10):1229-36.
Score: 0.041
-
Treatment of hepatitis C virus infection in people with opioid use disorder: a real-world study of elbasvir/grazoprevir in a US Department of Veterans Affairs population. Am J Drug Alcohol Abuse. 2022 07 04; 48(4):445-453.
Score: 0.037
-
Effectiveness of Elbasvir/Grazoprevir in patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States veterans population. Antiviral Res. 2020 02; 174:104698.
Score: 0.032
-
Risk of Hepatocellular Cancer Recurrence in Hepatitis C Virus+ Patients Treated with Direct-Acting Antiviral Agents. Dig Dis Sci. 2019 11; 64(11):3328-3336.
Score: 0.031
-
Real-world effectiveness of elbasvir/grazoprevir In HCV-infected patients in the US veterans affairs healthcare system. J Viral Hepat. 2018 11; 25(11):1270-1279.
Score: 0.029